Abstract
We have described two cases of Devic’s disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.
Sommario
Abbiamo descritto due casi di Malattia di Devic trattati con Rituximab con differente risposta terapeutica. I risultati indicano la possibilità di una non risposta precoce nei casi molto aggressivi. Sono necessari trial clinici ben strutturati per la valutazione dell’efficacia dei trattamenti in questa rara malattia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114
Ghezzi A, Bergamaschi R, Martinelli V et al and the Italian Devic’s Study Group (IDESG) (2004) Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 251:47–52
Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461
Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112
Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:474–477
Wingerchuk DM, Weinshenker BG (2005) Neuromyelitis optica. Curr Treat Options Neurol 7:173–182
Cree BAC, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272
Wingerchuk DM, Lennon VA, Pittok SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489
Lalive PH, Menge T, Barman I et al (2006) Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 67:176–177
Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957–963
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Capobianco, M., Malucchi, S., di Sapio, A. et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurol Sci 28, 209–211 (2007). https://doi.org/10.1007/s10072-007-0823-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-007-0823-z